Joint Approach

Joint Approach

By Musculoskeletal Infection SocietyScienceNatural Sciences
Download on the App Store

Joint Approach episodes

  • Dalbavancin/Oritavancin for Treatment of PJI Part 1

    Join hosts Jessica Seidelman, MD and Johannes Plate, MD, PhD as they have an in-depth discussion about long-lasting antibiotics with Vance Fowler, MD, MHS, Thomas Holland, MD,  and Thomas Lodise, PharmD, PhD in the first episode of this three-part series. Thanks to Osteal Therapeutics for sponsoring this episode. For more information about VT-X7, including the APEX clinical trials results, please visit Ostealtx.com

    FOLLOW us on X  @jointapproach or Instagram @jointapproachpodcast for more announcements and content, and reach out to us at [email protected]

     

     

    26 min
  • The Psychosocial Impact of Orthopedic Joint Infections

    In this follow-up conversation from the International Consensus Meeting on Infection, hosts Jessica Seidelman, MD and Johannes Plate, MD, PhD chat with Allison Lastinger, MD, FACP, and Ran Schwarzkopf, MD about the question: “How can we capture the physical and psychological impact of orthopedic infections on patients?”

    FOLLOW us on X  @jointapproach or Instagram @jointapproachpodcast for more announcements and content, and reach out to us at [email protected]

    35 min
  • Spinal Implant Infections Part 2

    Hosts Jessica Seidelman, MD and Johannes Plate, MD, PhD conclude the discussion on spinal implant infections with Geno Tai, MD, and Francis Lovecchio, MD. Thanks to Osteal Therapeutics for sponsoring this episode. For more information about VT-X7, including the APEX clinical trials results, please visit Ostealtx.com

    FOLLOW us on X  @jointapproach or Instagram @jointapproachpodcast for more announcements and content, and reach out to us at [email protected]

     

     

    35 min
  • Spinal Implant Infections Part 1

    Join hosts Jessica Seidelman, MD and Johannes Plate, MD, PhD as they discuss spinal implant infections with Gino Tai, MD, and Francis Lovecchio, MD in part 1 of this 2 part series. Thanks to Osteal Therapeutics for sponsoring this episode. For more information about VT-X7, including the APEX clinical trials results, please visit Ostealtx.com

    FOLLOW us on X  @jointapproach or Instagram @jointapproachpodcast for more announcements and content, and reach out to us at [email protected]

     

     

    35 min
  • Bugged and Baffled: A Case with Angela Hewlett and Curtis Hartman

    Join hosts Jessica Seidelman, MD and Johannes Plate, MD, PhD in this Case Study Series entitled Bugged and Baffled. In this episode, they discuss a challenging case with Angela Hewlett, MD, and Curtis Hartman, MD.

    Thanks to Biocomposites for sponsoring this episode. For more information about Biocomposites products STIMULAN®, NanoBone®, and genex®, please click here

    FOLLOW us on X  @jointapproach or Instagram @jointapproachpodcast for more announcements and content, and reach out to us at [email protected]

    36 min
  • Innovative Approaches to Bone and Joint Infections Part 3

    Host Jessica Seidelman, MD and guests Kerry LaPlante, Pharm.D., FCCP, FIDSA, FIDP, and Julie Ann Justo, Pharm.D. conclude this 3-part series with discussions on pipeline innovations and adjunctive strategies for treating challenging prosthetic joint infections. Topics include local antibiotic administration, phage therapy, and immunotherapy. Thanks to Osteal Therapeutics for sponsoring this episode. For more information about VT-X7, including the APEX clinical trials results, please visit Ostealtx.com

    Listen to Breakpoints: The SIDP Podcast

    References:

    “Antibiotic Therapy for 6 or 12 Weeks for Prosthetic Joint Infection” PMID 34042388

    “NDM-9 resistance to taniborbactam” PMID 36796395

    “Wide dissemination of Gram-negative bacteria producing the taniborbactam-resistant NDM-9 variant: a One Health concern” PMID 37394537

    IDSA 2024 Guidance on the Treatment of Antimicrobial Resistant Gram-Negative Infections https://www.idsociety.org/practice-guideline/amr-guidance/

    “Dalbavancin for the Treatment of Osteomyelitis in Adult Patients: A Randomized Clinical Trial of Efficacy and Safety” PMID 30648126

    “Corynebacterium striatum Prosthetic Joint Infection Successfully Treated with Long-Term Dalbavancin” PMID 36985124

    “Emergence of Dalbavancin, Vancomycin, and Daptomycin Nonsusceptible Staphylococcus aureus in a Patient Treated with Dalbavancin: Case Report and Isolate Characterization” PMID 35510938

    “Local antibiotic delivery via intra-articular catheter infusion for the treatment of periprosthetic joint infection: a systematic review” PMID 38691147

    “A High-Affinity Native Human Antibody Disrupts Biofilm from Staphylococcus aureus Bacteria and Potentiates Antibiotic Efficacy in a Mouse Implant Infection Model” PMID 26833157

    31 min
  • Innovative Approaches to Bone and Joint Infections Part 2

    Host Jessica Seidelman, MD and guests Kerry LaPlante, Pharm.D., FCCP, FIDSA, FIDP, and Julie Ann Justo, Pharm.D. continue discussing long-acting antibiotics, systemic vs. oral antibiotics, and drug and dosing perspectives in episode 2 of this 3-part conversation. This episode is sponsored by BONESUPPORT™, makers of CERAMENT® G with Gentamicin. CERAMENT G is an FDA-designated breakthrough device offering proven bone remodeling with reliable elution of broad-spectrum Gentamicin. CERAMENT G has a 96% success rate in eradication of infection in a single-stage for patients with fracture related infections and chronic osteomyelitis. To learn more and review CERAMENT G cases, visit their website at BONESUPPORT.com

    Listen to Breakpoints: The SIDP Podcast

    References:

    “Antibiotic Therapy for 6 or 12 Weeks for Prosthetic Joint Infection” PMID 34042388

    “NDM-9 resistance to taniborbactam” PMID 36796395 

    “Wide dissemination of Gram-negative bacteria producing the taniborbactam-resistant NDM-9 variant: a One Health concern” PMID 37394537

    IDSA 2024 Guidance on the Treatment of Antimicrobial Resistant Gram-Negative Infections https://www.idsociety.org/practice-guideline/amr-guidance/

    “Dalbavancin for the Treatment of Osteomyelitis in Adult Patients: A Randomized Clinical Trial of Efficacy and Safety” PMID 30648126

    “Corynebacterium striatum Prosthetic Joint Infection Successfully Treated with Long-Term Dalbavancin” PMID 36985124

    “Emergence of Dalbavancin, Vancomycin, and Daptomycin Nonsusceptible Staphylococcus aureus in a Patient Treated with Dalbavancin: Case Report and Isolate Characterization” PMID 35510938

    “Local antibiotic delivery via intra-articular catheter infusion for the treatment of periprosthetic joint infection: a systematic review” PMID 38691147

    “A High-Affinity Native Human Antibody Disrupts Biofilm from Staphylococcus aureus Bacteria and Potentiates Antibiotic Efficacy in a Mouse Implant Infection Model” PMID 26833157

    FOLLOW us on X  @jointapproach or Instagram @jointapproachpodcast for more announcements and content, and reach out to us at [email protected]

     

    26 min
  • Innovative Approaches to Bone and Joint Infections Part 1

    Host Jessica Seidelman, MD has an in-depth discussion with Kerry LaPlante, Pharm.D., FCCP, FIDSA, FIDP, and Julie Ann Justo, Pharm.D. in the opening episode of this 3-part series. They discuss why PJI infections are so difficult to treat, and advances in antimicrobial agents in the pipeline. This episode is sponsored by BONESUPPORT™, makers of CERAMENT® G with Gentamicin. CERAMENT G is an FDA-designated breakthrough device offering proven bone remodeling with reliable elution of broad-spectrum Gentamicin. CERAMENT G has a 96% success rate in eradication of infection in a single-stage for patients with fracture related infections and chronic osteomyelitis. To learn more and review CERAMENT G cases, visit their website at BONESUPPORT.com

    Listen to Breakpoints: The SIDP Podcast

    References:

    “Antibiotic Therapy for 6 or 12 Weeks for Prosthetic Joint Infection” PMID 34042388

    “NDM-9 resistance to taniborbactam” PMID 36796395

    “Wide dissemination of Gram-negative bacteria producing the taniborbactam-resistant NDM-9 variant: a One Health concern” PMID 37394537

    IDSA 2024 Guidance on the Treatment of Antimicrobial Resistant Gram-Negative Infections

    “Dalbavancin for the Treatment of Osteomyelitis in Adult Patients: A Randomized Clinical Trial of Efficacy and Safety” PMID 30648126

    “Corynebacterium striatum Prosthetic Joint Infection Successfully Treated with Long-Term Dalbavancin” PMID 36985124

    “Emergence of Dalbavancin, Vancomycin, and Daptomycin Nonsusceptible Staphylococcus aureus in a Patient Treated with Dalbavancin: Case Report and Isolate Characterization” PMID 35510938

    “Local antibiotic delivery via intra-articular catheter infusion for the treatment of periprosthetic joint infection: a systematic review” PMID 38691147

    “A High-Affinity Native Human Antibody Disrupts Biofilm from Staphylococcus aureus Bacteria and Potentiates Antibiotic Efficacy in a Mouse Implant Infection Model” PMID 26833157

    FOLLOW us on X  @jointapproach or Instagram @jointapproachpodcast for more announcements and content, and reach out to us at [email protected]

     

    37 min
  • Bugged and Baffled: Case 2 with Jenny Aronson

    Join hosts Jessica Seidelman, MD and Johannes Plate, MD, PhD in this Case Study Series entitled Bugged and Baffled. In this episode, they discuss another challenging case with Jenny Aronson, MD.  Thanks to Biocomposites for sponsoring this episode. For more information about Biocomposites products STIMULAN®, NanoBone®, and genex®, please click here

    FOLLOW us on X  @jointapproach or Instagram @jointapproachpodcast for more announcements and content, and reach out to us at [email protected]

    22 min
  • Bugged and Baffled: Case 1 with Jenny Aronson

    Join hosts Jessica Seidelman, MD and Johannes Plate, MD, PhD in this Case Study Series entitled Bugged and Baffled. In this episode, they discuss a the first of two challenging cases with Jenny Aronson, MD. Thanks to Biocomposites for sponsoring this episode. For more information about Biocomposites products STIMULAN®, NanoBone®, and genex®, please click here

    FOLLOW us on X  @jointapproach or Instagram @jointapproachpodcast for more announcements and content, and reach out to us at [email protected]

    28 min

About Joint Approach

From the publisher's feed

The goal of this podcast is to have both infectious disease physicians and orthopedic surgeons sit down to discuss the “joint” prevention, diagnosis and management of musculoskeletal infections. We…

More shows like Joint Approach

WSJ What’s News by The Wall Street Journal

WSJ What’s News

4,334 Listeners

JAMA Editors' Summary by JAMA Network

JAMA Editors' Summary

134 Listeners

This Week in Virology by Vincent Racaniello

This Week in Virology

2,055 Listeners

JAMA Clinical Reviews by JAMA Network

JAMA Clinical Reviews

498 Listeners

Editors in Conversation by American Society for Microbiology

Editors in Conversation

24 Listeners

The Curbsiders Internal Medicine Podcast by The Curbsiders Internal Medicine Podcast

The Curbsiders Internal Medicine Podcast

3,341 Listeners

The Clinical Problem Solvers by The Clinical Problem Solvers

The Clinical Problem Solvers

516 Listeners

Breakpoints by Society of Infectious Diseases Pharmacists

Breakpoints

170 Listeners

All-In with Chamath, Jason, Sacks & Friedberg by All-In Podcast, LLC

All-In with Chamath, Jason, Sacks & Friedberg

10,139 Listeners

Hard Fork by The New York Times

Hard Fork

5,549 Listeners

The Ezra Klein Show by New York Times Opinion

The Ezra Klein Show

15,896 Listeners

ID:IOTS - Infectious Disease Insight Of Two Specialists by Infectious Disease: Insights of Two Specialists

ID:IOTS - Infectious Disease Insight Of Two Specialists

29 Listeners

Infectious Disease Puscast by Vincent Racaniello

Infectious Disease Puscast

93 Listeners

NEJM AI Grand Rounds by NEJM Group

NEJM AI Grand Rounds

58 Listeners

Communicable by CMI Communications

Communicable

4 Listeners